Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

OBGEMSA 75 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/OBGEMSA 75 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

OBGEMSA 75 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Pierre Fabre Medicament🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 30, 2024
Approval ID: 7ac3f48a8344a67d
Company: Pierre Fabre Medicament
Type: Standard

Approval Details

Approval Id: 7ac3f48a8344a67d
Drug Cima Aemps Name: OBGEMSA 75 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 1241822001
Holder Company Name: Pierre Fabre Medicament
Marketing Company Name: Pierre Fabre Iberica S.A.
Holder Company Detail Path: /organization/pierre-fabre-medicament
Authorization Date: 2024-07-30
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 75 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Pierre Fabre Medicament
Company Detail Path: /organization/pierre-fabre-medicament

Company Information

Pharmaceutical Company Name: PIERRE FABRE MEDICAMENT
Country Name: India
City Name: mumbai,maharashtra,country_in
Address: P2, 3RD FLOOR, RAGHUVANSHI MILLS COMPOUND 11/12

Active Ingredients

VIBEGRON

75 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 30, 2024

Approval ID

7ac3f48a8344a67d

Type

Standard

Back to CIMA-AEMPS Approvals